Contents:

ASTHMA THERAPEUTICS A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability And Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions And Scope Of Study I-3 Inhaled Corticosteroids: I-3 Beta-2 Adrenoreceptor Agonists I-4 Combinations I-4 Anti- leukotrienes I-4 Others I-4 Antihistamines I-4 Methylxanthines I-4 Mast Cell Stabilizers I-5 Monoclonal Antibodies I-5 Anticholinergics I-5 II. 1. Market Overview II-1 Current & Future Analysis II-1 Competitive Outlook II-1 Major Asthma Therapeutics by Class II-2 Facts about Asthma II-2 2. Trends & Issues II-3 Combination Drugs Rule the World II-3 Novel Compounds To Pep Up Growth II-3 Rise in Pediatric Asthma To Keep Market Lucrative II-3 Toxic Nature of Asthma Drugs A Serious Concern II-3 Life Threatening Drugs Under Regulatory Scan II-3 3. Product Overview II-4 Causes of Asthma II-4 Allergens II-4 Irritants II-4 Other Factors II-4 Classes in Asthma II-5 A. Mild Intermittent Asthma: II-5 B. Mild Persistent Asthma: II-5 C. Moderate Persistent Asthma: II-5 D. Severe Persistent Asthma: II-5 Asthma Treatments II-6 Combination Asthma Medications II-6 Over-the-Counter Asthma Medications II-6 Immunotherapy (Allergy shots) II-6 Alternative Therapies II-6 Asthma Therapeutics II-6 Corticosteroids II-7 Beta-2 Adrenoreceptor Agonists II-7 Mast Cell Stabilizers II-7 Monoclonal Antibodies II-7 Immune System: Natural Defenders II-7 Human Antibodies II-8 Polyclonal and Monoclonal Antibodies II-8 Leukotriene Inhibitors II-8 Methylxanthines: II-8 Combination Therapeutics: II-8 Off Label Therapeutics: II-8 Anticholinergics: II-8 Antihistamines: II-9 Asthma Therapeutics by Various Classes II-9 4. Product Launches/Innovations II-10 Future to Witness A Novel Therapeutic in Asthma Treatment II-10 Dr. Reddy’s Releases Doxobid in India II-10 Novartis Files Approval for Xolair to Enter Japanese Market II-10 AstraZeneca Receives Approval for Symbicort II-10 GSK Alters Labels for Two Asthma Drugs II-10 DMI BioSciences Starts Evaluating DMI 8393 II-11 Inflazyme Begins Phase IIb Trial for IPL512,602 II-11 Neurim Develops A Neuroprotective Compound II-11 Xolair® Forays into UK II-11 Critical Therapeutics Rolls Out ZYFLO® II-11 Ivax Corp. Introduces Qvar EasiBreathe Inhaler II-12 Altana Rolls Out Respiratory Drug, Alvesco in the UK II-12 Sepracor Launches XOPENEX HFA II-12 Polyphor Commences Research for Protease Inhibitors II-12 Novartis Plans to Apply for A New Drug Approval II-12 Asmanex Twisthaler 220 mcg Receives US FDA Approval II-12 GroPep Completes Pre-Clinical Testing of T-Cell Peptide Drug II-13 Able Laboratories Obtains FDA Approval II-13 Acceleration Therapeutics’ AT-101 Passes Laboratory Test II-13 Pharmaxis’ New Tool to Assess Asthma Passes Clinical Trial II-13 Aventis Seeks FDA Approval Alvesco® II-13 Schering-Plough Releases Asmanex Twisthaler II-13 FDA Clears Xolair to Enter US Market II-14 Sepracor Completes Phase III Trial for XOPENEX II-14 Pfizer Conducts Phase II Clinical Studies II-14 Celera and Bayer Plans to End Collaboration II-14 Banyu and Kyorin Starts Distribution of Asthma Treatment II-14 GlaxoSmithKline Introduces Advair II-14 Novartis Gets FDA Approval for Foradil Aerolizer II-14 5. Recent Industry Activity II-15 Teva Purchases Ivax II-15 SkyePharma Strikes A Deal with KOSP II-15 Ranbaxy Inks an In-Licensing Agreement with Eurodrug II-15 Pfizer and Rigel Forms A Collaboration II-15 MAP and Elan Extends Agreement II-15 Glenmark Collaborates with Teijin Pharma II-16 Pfizer Acquires Meridica II-16 Bayer and Apax Forms A New Company II-16 KOSP Signs Multiple Agreements II-16 Novartis Pharma Inks A Licensing Agreement with Ivax II-17 LAB Intends to Purchase Seyvika II-17 ALTANA and Tanabe Signs A Pact II-17 6. Focus on Select Players II-18 Abbott Laboratories (US) II-18 ALTANA Pharma AG (Germany) II-18 AstraZeneca (UK) II-18 Boehringer Ingelheim (Germany) II-19 Genentech, Inc. (US) II-19 GlaxoSmithKline (UK) II-19 Merck & Co., Inc. (US) II-19 Novartis Pharma AG (Switzerland) II-19 Pfizer Inc. (US) II-20 Schering-Plough Corporation (US) II-20 Sepracor Inc. (US) II-20 The Sanofi-Aventis Group (US) II-21 3M (US) II-21 7. Global Market Perspective II-22 Table 1: World Recent Past, Current and Future Analysis for Asthma Therapeutics by Geographic Region US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-22 Table 2: World 10-Year Perspective for Asthma Therapeutics by Geographic Region Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-22 Table 3: World Recent Past, Current and Future Analysis for Inhaled Corticosteroids by Geographic Region US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-23 Table 4: World 10-Year Perspective for Inhaled Corticosteroids by Geographic Region Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/ Chart) II-23 Table 5: World Recent Past, Current and Future Analysis for Short Acting Beta Agonists by Geographic Region US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-24 Table 6: World 10-Year Perspective for Short Acting Beta Agonists by Geographic Region Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-24 Table 7: World Recent Past, Current and Future Analysis for Long Acting Beta Agonists by Geographic Region US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-25 Table 8: World 10-Year Perspective for Long Acting Beta Agonists by Geographic Region Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-25 Table 9: World Recent Past, Current and Future Analysis for Combinations by Geographic Region US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-26 Table 10: World 10-Year Perspective for Combinations by Geographic Region Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-26 Table 11: World Recent Past, Current and Future Analysis for Anti-Leukotrienes by Geographic Region US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-27 Table 12: World 10-Year Perspective for Anti-Leukotrienes by Geographic Region Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/ Chart) II-27 Table 13: World Recent Past, Current and Future Analysis for Other Asthma Therapeutics by Geographic Region US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-28 Table 14: World 10-Year Perspective for Other Asthma Therapeutics by Geographic Region Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-28 III. MARKET 1. The United States III-1 A.Market Analysis III-1 Current & Future Analysis III-1 Asthma Reflections in the US III-1 Competitive Scenario III-1 Table 15: Leading Anticholinergic Companies in the US (2006): Percentage Breakdown of Market Share for Boehringer Ingelheim, Dey Inc, Alpharma and Others (includes corresponding Graph/Chart) III-1 Product Launches/Innovations III-2 Strategic Developments III-4 Focus on Key Players III-5 3M III-5 Abbott Laboratories III-5 Genentech, Inc. III-5 Merck & Co., Inc. III-6 Pfizer Inc. III-6 Schering-Plough Corporation III-6 Sepracor Inc. III-6 The Sanofi-Aventis Group III-7 B.Market Analytics III-8 Table 16: US Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million ( includes corresponding Graph/Chart) III-8 Table 17: US 10-Year Perspective for Asthma Therapeutics by Product Segment Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-9 2. Canada III-10 A.Market Analysis III-10 Current & Future Analysis III-10 Product Launches/Innovations III-10 Strategic Development III-10 B.Market Analytics III-11 Table 18: Canadian Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-11 Table 19: Canadian 10-Year Perspective for Asthma Therapeutics by Product Segment Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/ Chart) III-12 3. Japan III-13 A.Market Analysis III-13 Current & Future Analysis III-13 Product Approvals/Launches III-13 Strategic Developments III-13 B.Market Analytics III-14 Table 20: Japanese Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets IndependentlyAnalyzed by Annual Sales for the Years 2000 through 2010 in US$ Million ( includes corresponding Graph/Chart) III-14 Table 21: Japanese 10-Year Perspective for Asthma Therapeutics by Product Segment Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/ Chart) III-15 4. Europe III-16 Market Analysis III-16 Current & Future Analysis III-16 Table 22: European Recent Past, Current and Future Analysis for Asthma Therapeutics by Geographic Region France, Germany, UK, Italy, Spain and Rest of Europe Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-16 Table 23: European Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-17 Table 24: European 10-Year Perspective for Asthma Therapeutics by Geographic Region Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain and Rest of Europe for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-18 Table 25: European 10-Year Perspective for Asthma Therapeutics by Product Segment Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/ Chart) III-19 4a. France III-20 Market Analysis III-20 Current & Future Analysis III-20 Table 26: French Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-20 Table 27: French 10-Year Perspective for Asthma Therapeutics by Product Segment Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-21 4b. Germany III-22 A.Market Analysis III-22 Current & Future Analysis III-22 Product Launches/Innovations III-22 Focus on Key Players III-22 ALTANA Pharma AG III-22 Boehringer Ingelheim III-22 B.Market Analytics III-23 Table 28: German Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-23 Table 29: German 10-Year Perspective for Asthma Therapeutics by Product Segment Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-24 4c. The United Kingdom III-25 A.Market Analysis III-25 Current & Future Analysis III-25 Product Launches/Innovations III-25 Strategic Developments III-26 Focus on Key Players III-26 AstraZeneca III-26 GlaxoSmithKline III-26 B.Market Analytics III-27 Table 30: UK Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-27 Table 31: UK 10-Year Perspective for Asthma Therapeutics by Product Segment Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-28 4d. Italy III-29 Market Analysis III-29 Current & Future Analysis III-29 Table 32: Italian Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-29 Table 33: Italian 10-Year Perspective for Asthma Therapeutics by Product Segment Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/ Chart) III-30 4e. Spain III-31 Market Analysis III-31 Current & Future Analysis III-31 Table 34: Spanish Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-31 Table 35: Spanish 10-Year Perspective for Asthma Therapeutics by Product Segment Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/ Chart) III-32 4f. Rest of Europe III-33 A.Market Analysis III-33 Current & Future Analysis III-33 Product Approvals/Launches III-33 Strategic Development III-34 Focus on Select Player III-34 Novartis Pharma AG (Switzerland) III-34 B.Market Analytics III-35 Table 36: Rest of Europe Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-35 Table 37: Rest of Europe 10-Year Perspective for Asthma Therapeutics by Product Segment Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/ Chart) III-36 5. Rest of World III-37 A.Market Analysis III-37 Current & Future Analysis III-37 Product Launches III-37 Strategic Developments III-37 B.Market Analytics III-38 Table 38: Rest of World Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-38 Table 39: Rest of World 10-Year Perspective for Asthma Therapeutics by Product Segment Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/ Chart) III-39 IV. COMPETITION 1. 3M Company (USA) IV-1 Table 40: First Quarter Sales Analysis: 2005-2006 (In US$ billion) IV-5 Table 41: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ billion) IV-5 Table 42: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-5 Table 43: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion) IV-5 Table 44: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-6 2. Abbott Laboratories (USA) IV-21 3. Able Laboratories, Inc. (USA) IV-30 4. Adams Respiratory Therapeutics (USA) IV-31 Table 45: Annual Sales Analysis: 2004-2006 (In US$ million) IV-31 Table 46: Annual Sales Analysis by Quarter: 2005-2006 (In US$ million) IV-32 Table 47: Annual Sales Analysis by Product: 2005-2006 (In US$ million) IV-32 Table 48: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-32 5. Aerovance, Inc. (USA) IV-34 6. Almirall Prodesfarma SA (Spain) IV-35 7. Alpharma USPD, Inc. (USA) IV-37 8. Altana Pharma AG (Germany) IV-38 Table 49: Annual Sales Analysis: 2004-2005 (In € billion) IV-39 Table 50: Annual Sales Analysis by Product Segment: 2004-2005 (In € billion) IV-39 Table 51: Annual Sales Analysis by Geographical Region: 2004-2005 (In € billion) IV-39 9. Amgen, Inc. (USA) IV-41 Table 52: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-42 Table 53: Annual Sales Analysis: 2004-2005 (In US$ million) IV-42 Table 54: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-42 10. Asthmatx, Inc. (USA) IV-45 11. Astrazeneca PLC (UK) IV-46 Table 55: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ Million) IV-48 Table 56: Half Yearly Sales Analysis By Quarter: 2005- 2006 (H1) (In US$ Million) IV-49 Table 57: Half Yearly Sales Analysis By Geographic Region: 2005-2006 (H1) (In US$ Million) IV-49 Table 58: Annual Sales Analysis By Quarter: 2004-2005 (In US$ Million) IV-49 Table 59: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ Million) IV-49 Astrazeneca Pharmaceuticals LP (USA) IV-59 12. Biocon India Limited (India) IV-63 Table 60: Annual Sales Analysis: 2004-2005 (In INR million) IV-64 13. Boehringer Ingelheim GmbH (Germany) IV-67 Boehringer Ingelheim Pharmaceuticals, Inc. (USA) IV-71 Boehringer Ingelheim Ltd. (Canada) IV-71 14. Breckenridge Pharmaceutical, Inc. (USA) IV-73 15. Cadila Pharmaceuticals Limited (India) IV-74 16. Cipla Ltd. (India) IV-77 17. Coley Pharmaceutical Group, Inc. (USA) IV-80 Table 61: Half-Yearly Sales Analysis: 2006-2005 (H1) (In Can$ thousands) IV-80 Table 62: Quarterly Sales Analysis: 2005-2004 (In Can$ thousands) IV-81 18. Cosmobio Co., Ltd. (Japan) IV-82 19. Critical Therapeutics, Inc. (USA) IV-84 Table 63: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-84 20. deCODE Genetics (Iceland) IV-86 Table 64: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-87 Table 65: Annual Sales Analysis: 2004-2005 (In US$ million) IV-87 Table 66: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-87 Table 67: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-87 21. DMI BioSciences, Inc. (USA) IV-89 22. Dr. Reddys Laboratories (India) IV-90 Table 68: First Quarter Sales Analysis: 2005-2006 (Q1) (In INR billion) IV-92 Table 69: Annual Sales Analysis: 2004-2005 (In INR billion) IV-92 Table 70: Annual Sales Analysis by Segment: 2004-2005 (In INR billion) IV-93 Table 71: Annual Sales Analysis by Geographic Region: 2004-2005 (In INR billion) IV-93 23. Elan Corporation Plc (Ireland) IV-97 Table 72: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-98 Table 73: Annual Sales Analysis: 2004-2005 (In US$ million) IV-98 Table 74: Annual Sales Analysis By Segment: 2004-2005 (In US$ million) IV-98 Table 75: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ million) IV-99 24. Epitomics, Inc. (USA) IV-101 25. Eurodrug Laboratories Group (The Netherlands) IV-103 26. Exim Pharm International (India) IV-104 27. F. Hoffmann-La Roche Ltd. (Switzerland) IV-106 Table 76: First Quarter Sales Analysis: 2005-2006 (In CHF billion) IV-107 Table 77: First Quarter Sales Analysis by Segment: 2005-2006 (In CHF billion) IV-107 Hoffmann-La Roche, Inc. (USA) IV-110 Genentech, Inc. (USA) IV-113 Table 78: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-115 Table 79: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) (Switzerland)) IV-115 28. Forest Laboratories, Inc. (USA) IV-119 Table 80: First Quarter Sales Analysis: 2006-2007 (In US$ billion) IV-120 Table 81: Annual Sales Analysis: 2004-2006 (In US$ billion) IV-120 Table 82: Annual Sales Analysis by Product: 2005-2006 (In US$ billion) IV-120 Table 83: Annual Sales Analysis by Geographic Region: 2005-2006 (In US$ billion) IV-121 Table 84: Quarterly Sales Analysis: 2005-2006 (In US$ billion) IV-121 29. Gilead Sciences (USA) IV-125 Table 85: Half Yearly Sales Analysis by Quarter: 2005- 2006 (H1) (In USS$ million) IV-126 Table 86: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In USS$ million) IV-126 Table 87: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-127 Table 88: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-127 30. Glaxosmithkline PLC (UK) IV-132 Table 89: Half Yearly Sales Analysis: 2005-2006 (H1) (In £ million) IV-133 Table 90: Half Yearly Sales Analysis by Segment: 2005- 2006 (H1) (In £ million) IV-133 Table 91: Annual Sales Analysis by Segment: 2004-2005 (In £ million) IV-133 Glaxosmithkline (USA) IV-142 31. Glenmark Pharmaceuticals Ltd. (India) IV-145 Glenmark Pharmaceuticals SA (Switzerland) IV-145 32. GroPep Limited (Australia) IV-146 Table 92: Annual Sales Analysis by Business Segment: 2005-2006 (In A$ million) IV-148 33. Indoco Remedies (India) IV-150 34. Inflazyme Pharmaceuticals Limited (Canada) IV-153 35. Janssen-Cilag GmbH (Austria) IV-155 36. Kos Pharmaceuticals, Inc. (USA) IV-156 Table 93: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-157 Table 94: Annual Sales Analysis: 2004-2005 (In US$ million) IV-157 37. Kyorin Pharmaceutical Co., Ltd. (Japan) IV-159 38. Lab International, Inc. (Canada) IV-160 Table 95: Annual Sales Analysis by Business Segment: 2004-2005 (In Can$ million) IV-161 Table 96: Annual Sales Analysis by Geographic Region: 2004-2005 (In Can$ million) IV-161 39. Lark Laboratories (India) IV-164 40. MAP Pharmaceuticals, Inc. (USA) IV-166 41. Mayne Pharma Pty, Ltd. (Australia) IV-167 Table 97: Annual Sales Analysis By Segment: 2004-2005 (In A$ Million) IV-167 Table 98: Annual Sales Analysis By Geographic Region: 2004-2005 (In A$ Million) IV-168 42. MediciNova, Inc. (USA) IV-171 Table 99: Half-Yearly Sales Analysis: 2005-2006 (H1) (In US$ Thousand) IV-171 43. Mercia Pharma, Inc. (USA) IV-175 44. Merck KGaA (Germany) IV-176 Table 100: Annual Sales Analysis Segment: 2004-2005 (In € million) IV-178 Merck & Co., Inc. (USA) IV-182 Table 101: Half Yearly Sales Analysis By Quarter: 2005 -2006 (H1) (In US$ million) IV-183 Table 102: Half Yearly Sales Analysis by Product: 2005 -2006 (H1) (In US$ million) IV-183 Table 103: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-183 Table 104: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-184 Banyu Pharmaceutical Co., Ltd. (Japan) IV-186 Dey, L.P. (USA) IV-187 45. Millennium Pharmaceuticals, Inc. (USA) IV-189 Table 105: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-189 Table 106: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-189 46. MorphoSys AG (Germany) IV-192 Table 107: First Quarter Sales Analysis: 2005-2006 (Q1) (In € million) IV-192 47. Neurim Pharmaceuticals (1991) Ltd. (Israel) IV-194 48. Nicholas Piramal India Ltd. (India) IV-195 Table 108: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-196 49. Novartis AG (Switzerland) IV-197 Table 109: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-200 Table 110: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In US$ million) IV-201 Table 111: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-201 Table 112: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-201 Novartis Pharma Switzerland AG (Switzerland) IV-209 Novartis Pharma GmbH (Germany) IV-210 Sandoz International GmbH (Germany) IV-210 50. Oriel Therapeutics, Inc. (USA) IV-212 51. Pfizer, Inc. (USA) IV-213 Table 113: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-215 Table 114: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In US$ billion) IV-215 Table 115: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion) IV-216 Pfizer Consumer Healthcare Division (USA) IV-220 52. Pharmaxis Ltd. (Australia) IV-224 53. Polyphor Limited (Switzerland) IV-226 54. Pure Pharma Limited (India) IV-228 55. Ranbaxy Laboratories Ltd. (India) IV-229 56. Rigel Pharmaceuticals, Inc. (USA) IV-243 Table 116: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-243 Table 117: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-244 57. Sanofi-Aventis (France) IV-245 Table 118: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million) IV-246 Table 119: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In € million) IV-246 Table 120: Annual Sales Analysis: 2004-2005 (In € million) IV-246 Table 121: Annual Sales Analysis by Segment: 2004-2005 (In € million) IV-246 Table 122: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million) IV-247 Sanofi-Aventis (USA) IV-252 58. Schering-Plough Corporation (USA) IV-254 Table 123: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In US$ million) IV-255 Table 124: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-256 Table 125: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-256 Table 126: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-256 AESCA Pharma GmbH (Austria) IV-260 59. Sepracor, Inc. (USA) IV-261 Table 127: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million) IV-261 Table 128: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-262 60. Shinpoong Pharmaceutical Co., Ltd. (South Korea) IV-265 61. SkyePharma PLC (UK) IV-266 Table 129: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In £ million) IV-267 Table 130: Annual Sales Analysis by Segment: 2004-2005 (In £ million) IV-267 Table 131: Annual Sales Analysis by Geographic Region: 2004-2005 (In £ million) IV-268 62. Sumit Laboratories (India) IV-271 63. Surya Pharmaceutical Ltd. (India) IV-272 64. Synairgen Research Limited (UK) IV-272 65. Tanabe Seiyaku Co., Ltd. (Japan) IV-273 Table 132: First Quarter Sales Analysis: 2006-2007 (Q1) (In US$ million) IV-273 Table 133: First Quarter Sales Analysis by Business Segment: 2005-2006 (Q1) (In Yen million) IV-274 Table 134: Annual Sales Analysis: 2005-2006 (In US$ million) IV-274 Table 135: Annual Sales Analysis by Business Segment: 2004-2005 (In Yen million) IV-274 66. TEVA Pharmaceutical Industries Ltd. (Israel) IV-277 Table 136: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million) IV-278 Table 137: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-278 IVAX Corporation (USA) IV-287 Table 138: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-289 Table 139: Quarterly Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-289 Table 140: Nine Months Sales Analysis by Product Category: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-289 Table 141: Nine Months Sales Analysis by Geographical Region: 2004-2005 (Nine Months Ended, September) (In US$ billion)Limited (Israel)) IV-290 Ivax Laboratories, Inc. (USA) IV-295 67. Trudell Medical International (Canada) IV-296 68. UCB SA (Belgium) IV-297 Table 142: Annual Sales Analysis: 2004-2005 (In € million) IV-297 Table 143: Annual Sales Analysis By Business Segment: 2004-2005 (In € million) IV-297 69. Zedawn Formulations (P) Ltd. (India) IV-300 70. Zenyth Therapeutics Limited (Australia) IV-301 Table 144: Annual Sales Analysis: 2004-2005 (In A$ million) IV-301

Companies Mentioned

- 3M Company (USA) - Abbott Laboratories (USA) - Able Laboratories, Inc (USA) - Adams Respiratory Therapeutics (USA) - Aerovance, Inc (USA) - Almirall Prodesfarma SA (Spain) - Alpharma USPD, Inc (USA) - Altana Pharma AG (Germany) - Amgen, Inc (USA) - Asthmatx, Inc (USA) - Astrazeneca PLC (UK) - Biocon India Limited (India) - Boehringer Ingelheim GmbH (Germany) - Breckenridge Pharmaceutical, Inc (USA) - Cadila Pharmaceuticals Limited (India) - Cipla Ltd (India) - Coley Pharmaceutical Group, Inc (USA) - Cosmobio Co, Ltd (Japan) - Critical Therapeutics, Inc (USA) - deCODE Genetics (Iceland) - DMI BioSciences, Inc (USA) - Dr Reddys Laboratories (India) - Elan Corporation Plc (Ireland) - Epitomics, Inc (USA) - Eurodrug Laboratories Group (The Netherlands) - Exim Pharm International (India) - F Hoffmann-La Roche Ltd (Switzerland) - Forest Laboratories, Inc (USA) - Gilead Sciences (USA) - Glaxosmithkline PLC (UK) - Glenmark Pharmaceuticals Ltd (India) - GroPep Limited (Australia) - Indoco Remedies (India) - Inflazyme Pharmaceuticals Limited (Canada) - Janssen-Cilag GmbH (Austria) - Kos Pharmaceuticals, Inc (USA) - Kyorin Pharmaceutical Co, Ltd (Japan) - Lab International, Inc (Canada) - Lark Laboratories (India) - MAP Pharmaceuticals, Inc (USA) - Mayne Pharma Pty, Ltd (Australia) - MediciNova, Inc (USA) - Mercia Pharma, Inc (USA) - Merck KGaA (Germany) - Millennium Pharmaceuticals, Inc (USA) - MorphoSys AG (Germany) - Neurim Pharmaceuticals () Ltd (Israel) - Nicholas Piramal India Ltd (India) - Novartis AG (Switzerland) - Oriel Therapeutics, Inc (USA) - Pfizer, Inc (USA) - Pharmaxis Ltd (Australia) - Polyphor Limited (Switzerland) - Pure Pharma Limited (India) - Ranbaxy Laboratories Ltd (India) - Rigel Pharmaceuticals, Inc (USA) - Sanofi-Aventis (France) - Schering-Plough Corporation (USA) - Sepracor, Inc (USA) - Shinpoong Pharmaceutical Co, Ltd (South Korea) - SkyePharma PLC (UK) - Sumit Laboratories (India) - Surya Pharmaceutical Ltd (India) - Synairgen Research Limited (UK) - Tanabe Seiyaku Co, Ltd (Japan) - TEVA Pharmaceutical Industries Ltd (Israel) - Trudell Medical International (Canada) - UCB SA (Belgium) - Zedawn Formulations (P) Ltd (India) - Zenyth Therapeutics Limited (Australia)